SCHEMBL29795000

SCHEMBL29795000

COc1ccccc1C12CCCN1C(=O)c1ccc(-c3cnc(N4CCOCC4)nc3)cc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
MAPT P10636 3/20 0.38
MEN1 O00255 3/20 0.38
TSHR P16473 3/20 0.38
KMT2A Q03164 3/20 0.38
KDM4E B2RXH2 2/20 0.38
ALOX15 P16050 1/20 0.38
AGER Q15109 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALOX5AP P20292 1/20 0.38
FEN1 P39748 1/20 0.38
ALDH1A1 P00352 2/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38
HIF1A Q16665 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18146383 1.00 LMNA (0.38) LMNAMAPTMEN1TSHRKMT2A
SCHEMBL19818294 0.67 TNF (0.45) ALOX5APFEN1WDR5PIK3CAMTOR
SCHEMBL19818295 0.67 TNF (0.45) ALOX5APFEN1WDR5PIK3CAMTOR
SCHEMBL19818293 0.67 TNF (0.45) ALOX5APFEN1WDR5PIK3CAMTOR
SCHEMBL29794977 0.66 TNF (0.41) LMNAMAPTMEN1TSHRKMT2A
SCHEMBL18145753 0.65 TNF (0.50) ALOX5APFEN1WDR5PIK3CACNR2
SCHEMBL18145710 0.65 TNF (0.48) ALOX5APFEN1WDR5PIK3CAMTOR
SCHEMBL18157271 0.65 TNF (0.50) ALOX5APFEN1WDR5PIK3CACNR2
SCHEMBL18145674 0.65 TNF (0.50) ALOX5APFEN1WDR5PIK3CACNR2
SCHEMBL18145676 0.65 TNF (0.50) ALOX5APFEN1WDR5PIK3CACNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260131007-A1 Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins AVILAR THERAPEUTICS, INC. (US) 2026-05-14 US disclosed
EP-4493221-A2 TARGETED BIFUNCTIONAL DEGRADERS Yale University (US) 2025-01-22 EP disclosed
CN-119212727-A Targeted bifunctional degradants 耶鲁大学 2024-12-27 CN disclosed
WO-2024182772-A2 MANNOSE 6-PHOSPHATE RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-09-06 WO disclosed
WO-2023178199-A2 TARGETED BIFUNCTIONAL DEGRADERS YALE UNIVERSITY (US) 2023-09-21 WO disclosed
CN-115315272-A Targeting difunctional degradation agent 耶鲁大学 2022-11-08 CN disclosed
EP-4041262-A1 TARGETED BIFUNCTIONAL DEGRADERS Yale University (US) 2022-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260131007-A1 Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins IGF2R, M6PR, MSR1 LMNA 3278/4885MAPT 4859/4885MEN1 3214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.